Licensing & Partnership Diligence
Evaluate regulatory status, submission history, approval risks, and compliance gaps for licensing or co-development deals.
Considering a licensing deal, strategic partnership, merger & acquisition, or investment? We provide thorough regulatory due diligence to identify key issues, risks, and opportunities — giving you a clear, unbiased, and confidential perspective.
Our detailed reports become a vital part of your decision-making and negotiation process, complementing your internal team with deep regulatory expertise and sound insights.
Contact Us
In licensing, partnerships, M&A, or investments, regulatory risks can significantly impact value, timelines, and success. We uncover hidden issues early — so you make informed decisions with confidence.
Uncover regulatory, compliance, and quality issues before they become costly problems.
Accurate due diligence safeguards your financial and strategic interests.
Leverage our findings to negotiate better terms and reduce post-deal surprises.
Confirm target assets meet global standards (FDA, EMA, CDSCO, etc.) before closing.
We deliver confidential, independent, and comprehensive regulatory due diligence for licensing, partnerships, M&A, and investments:
Evaluate regulatory status, submission history, approval risks, and compliance gaps for licensing or co-development deals.
Comprehensive review of regulatory portfolios, pending submissions, variations, post-approval commitments, and potential liabilities.
Regulatory risk scoring, timeline projections, cost-to-approval estimates, and impact on asset valuation for investors.
Identify gaps in GMP, pharmacovigilance, labelling, clinical data, and ongoing obligations across global markets.
Clear, actionable, unbiased reports tailored to your transaction goals — fully confidential and decision-ready.
Post-diligence recommendations on risk mitigation, integration planning, and future regulatory strategy.
We deliver independent, expert-driven insights that protect your investment and strengthen your position:
Independent analysis with complete confidentiality — no conflicts of interest.
Deep knowledge of FDA, EMA, CDSCO, ANVISA, PMDA, TGA, and other major frameworks.
Timely delivery of clear, decision-ready reports to support negotiations and closings.